KW-2149
KW-2149 (KT-6149) is a Mitomycin C analogue activated by serum. KW-2149 can interact with DNA. KW-2149 exhibits antitumor activity. KW-2149 has pulmonary toxicity KW-2149 can be used for the research of cancer, such as leukemia[1][2].
Product Specifications
CAS Number
118359-59-4
Product Name Alternative
KT-6149
UNSPSC
12352005
Target
DNA Alkylator/Crosslinker; Drug Derivative
Related Pathways
Cell Cycle/DNA Damage; Others
Field of Research
Cancer
Smiles
CO[C@]12N(C[C@@]3([H])[C@]2([H])N3)C4=C(C(C(NCCSSCCNC(CC[C@H](N)C(O)=O)=O)=C(C4=O)C)=O)[C@H]1COC(N)=O
Molecular Formula
C24H34N6O8S2
Molecular Weight
598.69
References & Citations
[1]Tsuruo T, et al. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2- (gamma-L-glutamylamino) ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo. Cancer Chemother Pharmacol. 1990;27 (2) :89-93.|[2]Schrijvers D, et al. KW-2149-induced pulmonary toxicity is not prevented by corticosteroids: a phase I and pharmacokinetic study. Anticancer Drugs. 1999 Aug;10 (7) :633-9|[3]McAdam SR, et al. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C) : DNA interactions and drug uptake following serum activation. Biochem Pharmacol. 1998 Jun 1;55 (11) :1777-83.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
